Mucopolysaccharidoses type I (MPS I) is an inherited metabolic disease characterized by a malfunction of the α-l-iduronidase (IDUA) enzyme leading to the storage of glycosaminoglycans in the lysosomes. This disease has longtime been studied as a therapeutic target for those studying gene therapy and many studies have been done using various vectors to deliver the IDUA gene for corrective treatment. Many vectors have difficulties with efficacy and insertional mutagenesis concerns including adeno-associated viral (AAV) vectors. Studies of AAV vectors treating MPS I have seemed promising, but recent deaths in gene therapy clinical trials for other inherited diseases using AAV vectors have left questions about their safety. Additionally, the recent modifications to adenoviral vectors leading them to target the vascular endothelium minimizing the risk of hepatotoxicity could lead to them being a viable option for MPS I gene therapy when coupled with gene editing technologies like CRISPR/Cas9.

Original languageEnglish
Pages (from-to)1088-1098
Number of pages11
JournalJournal of Inherited Metabolic Disease
Issue number5
StatePublished - Sep 2021


  • adenovirus
  • gene editing
  • gene therapy
  • mucopolysaccharidosis type I


Dive into the research topics of 'Mucopolysaccharidoses type I gene therapy'. Together they form a unique fingerprint.

Cite this